A randomized controlled trial comparing the effects of counseling and alarm device on HAART adherence and virologic outcomes

Michael H Chung, Barbra A Richardson, Kenneth Tapia, Sarah Benki-Nugent, James N Kiarie, Jane M Simoni, Julie Overbaugh, Mena Attwa, Grace C John-Stewart, Michael H Chung, Barbra A Richardson, Kenneth Tapia, Sarah Benki-Nugent, James N Kiarie, Jane M Simoni, Julie Overbaugh, Mena Attwa, Grace C John-Stewart

Abstract

Background: Behavioral interventions that promote adherence to antiretroviral medications may decrease HIV treatment failure. Antiretroviral treatment programs in sub-Saharan Africa confront increasing financial constraints to provide comprehensive HIV care, which include adherence interventions. This study compared the impact of counseling and use of an alarm device on adherence and biological outcomes in a resource-limited setting.

Methods and findings: A randomized controlled, factorial designed trial was conducted in Nairobi, Kenya. Antiretroviral-naïve individuals initiating free highly active antiretroviral therapy (HAART) in the form of fixed-dose combination pills (d4T, 3TC, and nevirapine) were randomized to one of four arms: counseling (three counseling sessions around HAART initiation), alarm (pocket electronic pill reminder carried for 6 months), counseling plus alarm, and neither counseling nor alarm. Participants were followed for 18 months after HAART initiation. Primary study endpoints included plasma HIV-1 RNA and CD4 count every 6 months, mortality, and adherence measured by monthly pill count. Between May 2006 and September 2008, 400 individuals were enrolled, 362 initiated HAART, and 310 completed follow-up. Participants who received counseling were 29% less likely to have monthly adherence <80% (hazard ratio [HR] = 0.71; 95% confidence interval [CI] 0.49-1.01; p = 0.055) and 59% less likely to experience viral failure (HIV-1 RNA ≥5,000 copies/ml) (HR 0.41; 95% CI 0.21-0.81; p = 0.01) compared to those who received no counseling. There was no significant impact of using an alarm on poor adherence (HR 0.93; 95% CI 0.65-1.32; p = 0.7) or viral failure (HR 0.99; 95% CI 0.53-1.84; p = 1.0) compared to those who did not use an alarm. Neither counseling nor alarm was significantly associated with mortality or rate of immune reconstitution.

Conclusions: Intensive early adherence counseling at HAART initiation resulted in sustained, significant impact on adherence and virologic treatment failure during 18-month follow-up, while use of an alarm device had no effect. As antiretroviral treatment clinics expand to meet an increasing demand for HIV care in sub-Saharan Africa, adherence counseling should be implemented to decrease the development of treatment failure and spread of resistant HIV.

Trial registration: ClinicalTrials.gov NCT00273780.

Conflict of interest statement

Academic Editor Edward Mills has collaborated and published one previous paper with Michael Chung, the lead author on this paper.

Figures

Figure 1. Trial profile.
Figure 1. Trial profile.
TB, tuberculosis.
Figure 2. Lowess curves of percent adherence…
Figure 2. Lowess curves of percent adherence over time in months since HAART initiation by intervention.
Thick lines indicate average percent adherence. Thin lines indicate 95% CIs. Solid lines indicate intervention. Dashed lines indicate no intervention. (A) Counseling versus no counseling. (B) Alarm versus no alarm.
Figure 3. Kaplan-Meier survival curves comparing counseling…
Figure 3. Kaplan-Meier survival curves comparing counseling versus no counseling and alarm versus no alarm.
Study outcomes include (A) adherence

References

    1. Harries AD, Nyangulu DS, Hargreaves NJ, Kaluwa O, Salaniponi FM. Preventing antiretroviral anarchy in sub-Saharan Africa. Lancet. 2001;358:410–414.
    1. Carlucci JG, Kamanga A, Sheneberger R, Shepherd BE, Jenkins CA, et al. Predictors of adherence to antiretroviral therapy in rural Zambia. J Acquir Immune Defic Syndr. 2008;47:615–622.
    1. Orrell C, Bangsberg DR, Badri M, Wood R. Adherence is not a barrier to successful antiretroviral therapy in South Africa. AIDS. 2003;17:1369–1375.
    1. Mills EJ, Nachega JB, Buchan I, Orbinski J, Attaran A, et al. Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis. JAMA. 2006;296:679–690.
    1. Calmy A, Pinoges L, Szumilin E, Zachariah R, Ford N, et al. Generic fixed-dose combination antiretroviral treatment in resource-poor settings: multicentric observational cohort. AIDS. 2006;20:1163–1169.
    1. Wools-Kaloustian K, Kimaiyo S, Diero L, Siika A, Sidle J, et al. Viability and effectiveness of large-scale HIV treatment initiatives in sub-Saharan Africa: experience from western Kenya. AIDS. 2006;20:41–48.
    1. Stringer JS, Zulu I, Levy J, Stringer EM, Mwango A, et al. Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. JAMA. 2006;296:782–793.
    1. Cressey TR, Jourdain G, Lallemant MJ, Kunkeaw S, Jackson JB, et al. Persistence of nevirapine exposure during the postpartum period after intrapartum single-dose nevirapine in addition to zidovudine prophylaxis for the prevention of mother-to-child transmission of HIV-1. J Acquir Immune Defic Syndr. 2005;38:283–288.
    1. Martin M, Del Cacho E, Codina C, Tuset M, De Lazzari E, et al. Relationship between adherence level, type of the antiretroviral regimen, and plasma HIV type 1 RNA viral load: a prospective cohort study. AIDS Res Hum Retroviruses. 2008;24:1263–1268.
    1. Bangsberg DR. Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clin Infect Dis. 2006;43:939–941.
    1. Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21–30.
    1. Maggiolo F, Ravasio L, Ripamonti D, Gregis G, Quinzan G, et al. Similar adherence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors. Clin Infect Dis. 2005;40:158–163.
    1. Nachega JB, Hislop M, Dowdy DW, Chaisson RE, Regensberg L, et al. Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes. Ann Intern Med. 2007;146:564–573.
    1. Ford N, Nachega JB, Engel ME, Mills EJ. Directly observed antiretroviral therapy: a systematic review and meta-analysis of randomised clinical trials. Lancet. 2009;374:2064–2071.
    1. Nachega JB, Mills EJ, Schechter M. Antiretroviral therapy adherence and retention in care in middle-income and low-income countries: current status of knowledge and research priorities. Curr Opin HIV AIDS. 5:70–77.
    1. Katabira ET, Oelrichs RB. Scaling up antiretroviral treatment in resource-limited settings: successes and challenges. AIDS. 2007;21(Suppl 4):S5–10.
    1. Wagner G, Ryan G, Taylor S. Formative evaluation of antiretroviral therapy scale-up efficiency in sub-Saharan Africa. AIDS Patient Care STDS. 2007;21:871–888.
    1. Ferradini L, Jeannin A, Pinoges L, Izopet J, Odhiambo D, et al. Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment. Lancet. 2006;367:1335–1342.
    1. Severe P, Leger P, Charles M, Noel F, Bonhomme G, et al. Antiretroviral therapy in a thousand patients with AIDS in Haiti. N Engl J Med. 2005;353:2325–2334.
    1. Behforouz HL, Farmer PE, Mukherjee JS. From directly observed therapy to accompagnateurs: enhancing AIDS treatment outcomes in Haiti and in Boston. Clin Infect Dis. 2004;38(Suppl 5):S429–436.
    1. Rueda S, Park-Wyllie LY, Bayoumi AM, Tynan AM, Antoniou TA, et al. Patient support and education for promoting adherence to highly active antiretroviral therapy for HIV/AIDS. Cochrane Database Syst Rev. 2006;3:CD001442.
    1. Simoni JM, Pearson CR, Pantalone DW, Marks G, Crepaz N. Efficacy of interventions in improving highly active antiretroviral therapy adherence and HIV-1 RNA viral load. A meta-analytic review of randomized controlled trials. J Acquir Immune Defic Syndr. 2006;43(Suppl 1):S23–S35.
    1. Pearson CR, Micek MA, Simoni JM, Hoff PD, Matediana E, et al. Randomized control trial of peer-delivered, modified directly observed therapy for HAART in Mozambique. J Acquir Immune Defic Syndr. 2007;46:238–244.
    1. Sarna A, Luchters S, Geibel S, Chersich MF, Munyao P, et al. Short- and long-term efficacy of modified directly observed antiretroviral treatment in Mombasa, Kenya: a randomized trial. J Acquir Immune Defic Syndr. 2008;48:611–619.
    1. McNeil DGJ. The New York Times; 2010. Jul 22, Drug war statement upstaged at AIDS gathering.
    1. McNeil DGJ. The New York Times; 2010. May 9, As the need grows, the money for AIDS runs far short.
    1. McNeil DGJ. The New York Times; 2010. May 10, At front lines, global war on AIDS is falling apart.
    1. Frick P, Tapia K, Grant P, Novotny M, Kerzee J. The effect of a multidisciplinary program on HAART adherence. AIDS Patient Care STDS. 2006;20:511–524.
    1. Frick PA, Lavreys L, Mandaliya K, Kreiss JK. Impact of an alarm device on medication compliance in women in Mombasa, Kenya. Int J STD AIDS. 2001;12:329–333.
    1. Chung MH, Drake AL, Richardson BA, Reddy A, Thiga J, et al. Impact of prior HAART use on clinical outcomes in a large Kenyan HIV treatment program. Curr HIV Res. 2009;7:441–446.
    1. Ojoo S, editor. Nairobi: National AIDS and STI Control Program (NASCOP); 2007. Kenya national clinical manual for ART providers: a concise and practical guide to ART provision.2nd edition.70
    1. Fisher JD, Fisher WA, Misovich SJ, Kimble DL, Malloy TE. Changing AIDS risk behavior: effects of an intervention emphasizing AIDS risk reduction information, motivation, and behavioral skills in a college student population. Health Psychol. 1996;15:114–123.
    1. Miller WR, Rose GS. Toward a theory of motivational interviewing. Am Psychol. 2009;64:527–537.
    1. Emery S, Bodrug S, Richardson BA, Giachetti C, Bott MA, et al. Evaluation of performance of the Gen-Probe human immunodeficiency virus type 1 viral load assay using primary subtype A, C, and D isolates from Kenya. J Clin Microbiol. 2000;38:2688–2695.
    1. World Health Organization. Geneva: World Health Organization Press; 2010. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach.
    1. Pocock SJ, Assmann SE, Enos LE, Kasten LE. Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: current practice and problems. Stat Med. 2002;21:2917–2930.
    1. Tuldra A, Fumaz CR, Ferrer MJ, Bayes R, Arno A, et al. Prospective randomized two-Arm controlled study to determine the efficacy of a specific intervention to improve long-term adherence to highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2000;25:221–228.
    1. Mannheimer S, Friedland G, Matts J, Child C, Chesney M. The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials. Clin Infect Dis. 2002;34:1115–1121.
    1. Sethi AK, Celentano DD, Gange SJ, Moore RD, Gallant JE. Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance. Clin Infect Dis. 2003;37:1112–1118.
    1. Mannheimer SB, Morse E, Matts JP, Andrews L, Child C, et al. Sustained benefit from a long-term antiretroviral adherence intervention. Results of a large randomized clinical trial. J Acquir Immune Defic Syndr. 2006;43(Suppl 1):S41–47.
    1. Rathbun RC, Farmer KC, Stephens JR, Lockhart SM. Impact of an adherence clinic on behavioral outcomes and virologic response in treatment of HIV infection: a prospective, randomized, controlled pilot study. Clin Ther. 2005;27:199–209.
    1. Pradier C, Bentz L, Spire B, Tourette-Turgis C, Morin M, et al. Efficacy of an educational and counseling intervention on adherence to highly active antiretroviral therapy: French prospective controlled study. HIV Clin Trials. 2003;4:121–131.
    1. Cooperman NA, Arnsten JH. Motivational interviewing for improving adherence to antiretroviral medications. Curr HIV/AIDS Rep. 2005;2:159–164.
    1. Watt MH, Maman S, Earp JA, Eng E, Setel PW, et al. “It's all the time in my mind”: facilitators of adherence to antiretroviral therapy in a Tanzanian setting. Soc Sci Med. 2009;68:1793–1800.
    1. Wise J, Operario D. Use of electronic reminder devices to improve adherence to antiretroviral therapy: a systematic review. AIDS Patient Care STDS. 2008;22:495–504.
    1. Simoni JM, Huh D, Frick PA, Pearson CR, Andrasik MP, et al. Peer support and pager messaging to promote antiretroviral modifying therapy in Seattle: a randomized controlled trial. J Acquir Immune Defic Syndr. 2009;52:465–473.
    1. Lester RT, Ritvo P, Mills EJ, Kariri A, Karanja S, et al. Effects of a mobile phone short message service on antiretroviral treatment adherence in Kenya (WelTel Kenya1): a randomised trial. Lancet. 2010;376:1838–1845.
    1. Donnelly J. Prevention urged in AIDS fight; Natsios says funds should spend less on HIV treatment. Boston Globe 2001 Jun 7;
    1. Amico KR, Harman JJ, Johnson BT. Efficacy of antiretroviral therapy adherence interventions: a research synthesis of trials, 1996 to 2004. J Acquir Immune Defic Syndr. 2006;41:285–297.
    1. Chung MH, Kohler P, Attwa M, Thiga J, John-Stewart GC. Comparing clinic retention between residents and nonresidents of Kibera, Kenya. J Acquir Immune Defic Syndr. 2010;53:422–424.
    1. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353:487–497.
    1. Gill CJ, Hamer DH, Simon JL, Thea DM, Sabin LL. No room for complacency about adherence to antiretroviral therapy in sub-Saharan Africa. AIDS. 2005;19:1243–1249.
    1. Mellors JW, Rinaldo CR, Jr., Gupta P, White RM, Todd JA, et al. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science. 1996;272:1167–1170.
    1. Aldous JL, Haubrich RH. Defining treatment failure in resource-rich settings. Curr Opin HIV AIDS. 2009;4:459–466.
    1. Hosseinipour MC, van Oosterhout JJ, Weigel R, Phiri S, Kamwendo D, et al. The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. AIDS. 2009;23:1127–1134.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner